Oncolytics Biotech (ONCY) COO discloses 500,000-share stock option holding
Rhea-AI Filing Summary
ONCOLYTICS BIOTECH INC Chief Operating Officer John Bearden reported holding stock options linked to 500,000 Common Shares. These options have an exercise price of $0.97 per share and expire on January 12, 2031. The option vests 50% on January 12, 2027, 25% on January 12, 2028, and 25% on January 12, 2029, subject to his continued service or employment on each vesting date.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
McAdory John Bearden
Role
Chief Operating Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Stock Options | -- | -- | -- |
Holdings After Transaction:
Stock Options — 500,000 shares (Direct)
Footnotes (1)
- F1. The stock option vests in three installments: 50% vesting on January 12, 2027; 25% vesting on January 12, 2028; and 25% vesting on January 12, 2029, subject to the Reporting Person's continued service or employment, as applicable, on each such vesting date.
Key Figures
Underlying shares: 500,000 Common Shares
Exercise price: $0.97 per share
Expiration date: January 12, 2031
+3 more
6 metrics
Underlying shares
500,000 Common Shares
Stock options underlying security shares reported as held
Exercise price
$0.97 per share
Stock option exercise price
Expiration date
January 12, 2031
Stock option expiration
Vesting 50%
January 12, 2027
First vesting installment (50% of option)
Vesting 25% (second)
January 12, 2028
Second vesting installment (25% of option)
Vesting 25% (third)
January 12, 2029
Third vesting installment (25% of option)
Key Terms
Stock Options, Common Shares, exercise price, vesting, +1 more
5 terms
Stock Options financial
"security_title: "Stock Options""
Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.
exercise price financial
"conversion_or_exercise_price: "0.9700""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"The stock option vests in three installments: 50% vesting on January 12, 2027..."
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
Reporting Person regulatory
"subject to the Reporting Person's continued service or employment"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider position does ONCY COO John Bearden report on this Form 3?
John Bearden reports holding stock options tied to 500,000 Common Shares of Oncolytics Biotech Inc. These options are disclosed as a derivative position, not as a recent purchase or sale of common shares in the open market.
What is the exercise price of John Bearden’s Oncolytics (ONCY) stock options?
The disclosed stock options have an exercise price of $0.97 per share. This means Bearden can acquire Common Shares at $0.97 if he exercises the options, subject to the vesting schedule and the options remaining outstanding until expiration.
When do John Bearden’s ONCY stock options vest according to the filing?
The option vests in three installments: 50% on January 12, 2027, 25% on January 12, 2028, and 25% on January 12, 2029. Each vesting tranche depends on Bearden’s continued service or employment on the respective vesting date.
What is the expiration date of the stock options reported by ONCY’s COO?
The stock options reported by John Bearden expire on January 12, 2031. After this expiration date, any unexercised portion of the options would no longer be exercisable under the terms described in the Form 3 and related footnote.